P3 HEALTH PARTNERS INC - PIII STOCK NEWS

P3 Health Partners Inc. (NASDAQ: PIII) plans to release its financial results for the fourth quarter and full year ending December 31, 2022, on March 30, 2023. The company will also file its Annual Report on Form 10-K on the same day. An investor call and webcast are scheduled for 4:30 PM ET to discuss the financial performance and provide a corporate update. P3 Health Partners focuses on improving healthcare through a network of over 2,800 affiliated primary care providers across five states. Further details will be available on their investor relations page.

P3 Health Partners Inc. (NASDAQ: PIII) announced its intention to file the Annual Report on Form 10-K by March 30, 2023. The delay is attributed to an administrative issue related to the delayed audit for 2021. P3 reaffirmed its 2022 revenue guidance of $1.025 billion to $1.075 billion, representing a 61% to 69% increase year-over-year. They expect at-risk Medicare Advantage membership to exceed 100,000, a 35% rise from 2021. The 2023 guidance includes revenue expectations of $1.20 billion to $1.25 billion and an Adjusted EBITDA loss of $40 million to $60 million. P3 anticipates achieving Adjusted EBITDA profitability by 2024.

P3 Health Partners Inc. (NASDAQ: PIII), a physician-led population health management company, announced that Dr. Amir Bacchus, Co-founder and Chief Medical Officer, will participate in a fireside chat at the Jefferies Value-Based Care Summit in Miami Beach, FL on March 13, 2023, at 2:45 PM ET. Additionally, Dr. Bacchus will present at the Barclays Global Healthcare Conference on March 14, 2023, at 4:35 PM ET, with a live audio webcast available. P3 Health Partners is committed to improving healthcare outcomes through value-based care coordination, managing over 2,800 affiliated primary care providers across five states.

P3 Health Partners Inc. (NASDAQ: PIII) has announced that CEO Dr. Sherif Abdou will present at the TD Cowen 43rd Annual Health Care Conference in Boston on March 7, 2023, at 1:30 PM Eastern Time. The presentation will include insights into the company's patient-centered healthcare model and strategies for improving patient outcomes. A live audio webcast of the presentation will be available on P3’s website, along with a replay for 30 days post-event. P3 Health Partners focuses on population health management, collaborating with over 2,800 primary care providers across five states.

P3 Health Partners Inc. (NASDAQ: PIII) is participating in J.P. Morgan’s 41st Annual Healthcare Conference in San Francisco from January 9-12, 2023. The Company reaffirms its 2022 revenue guidance of $1.025 billion to $1.075 billion, reflecting a 61% to 69% increase from 2021. For 2023, P3 expects Medicare Advantage membership to grow to 115,000-120,000 and revenue between $1.20 billion and $1.25 billion. Adjusted EBITDA loss is forecasted at $40 million to $60 million, with expectations for positive Adjusted EBITDA in 2024.

P3 Health Partners Inc. (NASDAQ: PIII) will participate in J.P. Morgan’s 41st Annual Healthcare Conference in San Francisco from January 9-12, 2023. Dr. Sherif Abdou, the co-founder and CEO, is scheduled to present on January 11 at 5:15 pm Pacific Time. A live audio webcast of the presentation will be accessible here, with a replay available for 30 days on P3's investor relations webpage. P3 Health Partners focuses on population health management, serving over 100,000 patients with a network of 2,500 providers in five states.

P3 Health Partners Inc. (NASDAQ: PIII) announced the appointment of Atul Kavthekar as Chief Financial Officer (CFO), effective December 12, 2022. He will oversee the company's finance organization, including Accounting, Treasury, Finance Analytics, and Investor Relations. Erin Darakjian, who served as interim CFO, will continue as Senior Vice President and Chief Accounting Officer. Kavthekar brings extensive financial experience from various industries, aiming to enhance P3's growth and patient care transformation.

P3 Health Partners reported a 59% revenue growth in Q3 2022, totaling $248.3 million, up from $156.2 million in Q3 2021. However, net loss increased to $65.3 million, compared to $32.1 million a year prior, primarily due to a $851.5 million goodwill impairment charge. Year-to-date revenue stands at $791.3 million, a 75% increase year-over-year. Adjusted EBITDA loss for the first nine months was $87.9 million, worse than the prior year's $59.9 million. Guidance for full-year Adjusted EBITDA loss has been revised to $118-$128 million.

P3 Health Partners Inc. (NASDAQ: PIII) will release its third-quarter financial results for the period ended September 30, 2022, on November 14, 2022, at 4:30 PM ET. A conference call will follow the release to provide corporate and financial updates. Investors can access this call via a toll-free number or through a live webcast available on the company's investor website. The conference aims to enhance transparency around P3's performance and future strategies.